 |
424 Diseases |  |
811 Trials |
|
811 Trials |  |
14499 News |  |
| «12...137138139140141142143144145146147...236237» |
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Apr 22, 2021
P1b/2, N=68, Suspended, Sponsor: Mayo Clinic
Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Apr 22, 2021
P1, N=430, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022 Trial completion date: Sep 2021 --> May 2021 | Trial primary completion date: Sep 2021 --> May 2021
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Metastases: Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (clinicaltrials.gov) - Apr 22, 2021
P2, N=90, Active, not recruiting, Sponsor: Yonsei University
Trial completion date: Sep 2021 --> May 2021 | Trial primary completion date: Sep 2021 --> May 2021 Trial completion date: May 2021 --> Aug 2021
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Apr 22, 2021
P2, N=17, Active, not recruiting, Sponsor: University of Southern California
Trial completion date: May 2021 --> Aug 2021 Trial completion date: Aug 2020 --> Aug 2022 | Trial primary completion date: May 2020 --> Aug 2021
- | Bylantra (devimistat) / Cornerstone Pharma
Trial completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 22, 2021
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Aug 2020 --> Aug 2022 | Trial primary completion date: May 2020 --> Aug 2021 Trial completion date: Mar 2021 --> Jul 2021
- || Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Apr 22, 2021
P2, N=75, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Mar 2021 --> Jul 2021 Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- ||| Ziihera (zanidatamab-hrii) / Jazz
Enrollment change, Trial completion date, Trial primary completion date: ZWI-ZW25-201: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (clinicaltrials.gov) - Apr 22, 2021
P2, N=362, Recruiting, Sponsor: Zymeworks Inc.
Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022 N=146 --> 362 | Trial completion date: Jan 2023 --> Apr 2024 | Trial primary completion date: Feb 2022 --> Mar 2023
- || Lumakras (sotorasib) / Amgen
Phase classification, Trial completion date, Monotherapy, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Apr 22, 2021
P1b/2, N=1013, Recruiting, Sponsor: Amgen
N=146 --> 362 | Trial completion date: Jan 2023 --> Apr 2024 | Trial primary completion date: Feb 2022 --> Mar 2023 Phase classification: P1b --> P1b/2 | Trial completion date: Jul 2027 --> Oct 2025
- || celecoxib oral / Generic mfg.
Clinical, Journal: Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. (Pubmed Central) - Apr 22, 2021
P3
Aspirin and cyclooxygenase 2 (COX-2) inhibitors have been associated with a reduced risk of colorectal polyps and cancer in observational and randomized studies...To determine if the addition of celecoxib to adjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) improves disease-free survival in patients with stage III colon cancer...Among patients with stage III colon cancer, the addition of celecoxib for 3 years, compared with placebo, to standard adjuvant chemotherapy did not significantly improve disease-free survival. ClinicalTrials.gov Identifier: NCT01150045.
- | Avastin (bevacizumab) / Roche
New trial, Metastases: FIRE-7: Centralized Tumour Board and Secondary Intervention Rate in mCRC (clinicaltrials.gov) - Apr 20, 2021
P, N=130, Not yet recruiting, Sponsor: Ludwig-Maximilians - University of Munich
- || docetaxel / Generic mfg.
Clinical, Journal: Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. (Pubmed Central) - Apr 20, 2021
The results of the current study indicate that also an intensification of neoadjuvant chemotherapy with 6 preoperative cycles of FLOT does not significantly increase perioperative complications. Thus, prolonged neoadjuvant chemotherapy with FLOT is safe for patients with locally advanced GC or GEJ tumors.
- || docetaxel / Generic mfg.
Clinical, Journal: Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. (Pubmed Central) - Apr 20, 2021
The quantification of TUBB3 might be considered as a negative predictive biomarker of benefit from taxane-based therapy in GC. Studies are needed to evaluate its role in the neoadjuvant setting.
- ||| BMS-813160 / BMS, Opdivo (nivolumab) / BMS
Enrollment closed, Trial primary completion date: A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 20, 2021
P1b/2, N=332, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Studies are needed to evaluate its role in the neoadjuvant setting. Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2022 --> Feb 2023
- ||||| EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
Enrollment closed, Metastases: EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (clinicaltrials.gov) - Apr 20, 2021
P3, N=218, Active, not recruiting, Sponsor: SynCore Biotechnology Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2022 --> Feb 2023 Recruiting --> Active, not recruiting
- | Enrollment open, Trial completion date, Trial primary completion date: Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer (clinicaltrials.gov) - Apr 19, 2021
P2, N=30, Recruiting, Sponsor: China Medical University, China
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: May 2021 --> Oct 2021 | Trial primary completion date: May 2020 --> Oct 2021
- | Enrollment open, Trial completion date, Trial primary completion date, Metastases: Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer (clinicaltrials.gov) - Apr 19, 2021
P2, N=30, Recruiting, Sponsor: China Medical University, China
Not yet recruiting --> Recruiting | Trial completion date: May 2021 --> Oct 2021 | Trial primary completion date: May 2020 --> Oct 2021 Not yet recruiting --> Recruiting | Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2020 --> Oct 2021
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Enrollment closed, Trial primary completion date: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Apr 19, 2021
P2, N=78, Active, not recruiting, Sponsor: Kristen Spencer
Not yet recruiting --> Recruiting | Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2020 --> Oct 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2020 --> Dec 2021
- ||| irinotecan / Generic mfg.
Clinical, P3 data, Journal: Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. (Pubmed Central) - Apr 18, 2021
P3
The significantly improved disease-free survival in the neoadjuvant chemotherapy group and the decreased neurotoxicity indicates that the perioperative approach is more efficient and better tolerated than adjuvant chemotherapy. Therefore, the PRODIGE 23 results might change clinical practice.
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, P2 data, Journal, Combination therapy, Tumor Mutational Burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). (Pubmed Central) - Apr 17, 2021
P2
have been enrolled. NIVACOR is registered at ClinicalTrials.gov: NCT04072198 , August 28, 2019.
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
Clinical: Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for metastatic #pancreascancer. Progress in a dreadful disease. Just published in @ESMO_Open by @myESMO https://t.co/jUggjVjIwh (Twitter) - Apr 17, 2021
- | Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus
Journal: Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. (Pubmed Central) - Apr 16, 2021
Grade 3/4 treatment-related adverse events that were more frequent in the LeToHAIC group than in the lenvatinib group included neutropenia (8.5% versus 1.2%), thrombocytopenia (5.6% versus 0), and nausea (5.6% versus 0). Lenvatinib, toripalimab, plus HAIC had acceptable toxic effects and might improve survival compared with lenvatinib alone in advanced hepatocellular carcinoma.
- | Avastin (bevacizumab) / Roche
Journal: Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban. (Pubmed Central) - Apr 15, 2021
Eight months later, the complete dissolution of the thrombus and recanalization of the portal vein were attained. Our case suggests that PVT can occur during bevacizumab-containing chemotherapy, and DOAC therapy might be beneficial for treating PVT in patients with cancer.
- || methotrexate / Generic mfg.
Clinical, Journal: The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia. (Pubmed Central) - Apr 15, 2021
These results suggest that the increase in RBC folate levels does not seem to have a large effect on RBC MTX levels. Future studies, assessing competition of Leucovorin and MTX on other cellular mechanisms which might negatively affect treatment efficacy, are necessary.
- | Enrollment open: Evaluation of a Folic Acid Wound Treatment (FAWT) for Chronic, Early-Stage Diabetic Foot Ulcer (DFU) Healing (clinicaltrials.gov) - Apr 14, 2021
P2, N=30, Recruiting, Sponsor: Joseph Boykin, MD
Future studies, assessing competition of Leucovorin and MTX on other cellular mechanisms which might negatively affect treatment efficacy, are necessary. Not yet recruiting --> Recruiting
- leucovorin calcium / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
[VIRTUAL] METHOTREXATE USE IN END-STAGE RENAL DISEASE: A CASE REPORT () - Apr 14, 2021 - Abstract #ASPHO2021ASPHO_545;
On week 4,5,9 and 10 of therapy she received methotrexate at 25% of protocol dose (3 gm/m^2 in place of 13 gm/m^2), with high dose leucovorin 50 mg/m2, with twice daily hemodialysis and cleared methotrexate at ~120 hours after each dose... Methotrexate can safely be used in renal failure with an interdisciplinary approach.
- cladribine / Generic mfg.
[VIRTUAL] ATYPICAL PRESENTATION AND MANAGEMENT OF JUVENILE XANTHOGRANULOMA () - Apr 14, 2021 - Abstract #ASPHO2021ASPHO_509;
Atypical clinical cases such as this should be reviewed to help clinicians understand the disease course and provide better care for patients. 1.
- leucovorin calcium / Generic mfg., vincristine / Generic mfg.
[VIRTUAL] SIGNIFICANTLY DELAYED METHOTREXATE CLEARANCE IN A PATIENT WITH PRE-B ALL AND COVID-19 () - Apr 14, 2021 - Abstract #ASPHO2021ASPHO_476;
This is a case of significantly delayed methotrexate clearance in a patient with HR pre-B ALL in the setting of asymptomatic COVID-19 infection. Further research is needed to characterize the effect of COVID-19 on these patients in order to make recommendations for treatment modifications when these patients have COVID-19 infections.
- dexamethasone / Generic mfg., methotrexate IV / Generic mfg.
[VIRTUAL] DEXTROMETHORPHAN ROLE IN THE FIRST TWENTY-FOUR HOURS OF METHOTREXATE-INDUCED-NEUROTOXICITY () - Apr 14, 2021 - Abstract #ASPHO2021ASPHO_457;
The results of this case are comparable to previous reports with the improvement of symptoms by four-fold compared with patients who had delayed or no treatment with dextromethorphan. Also, an NMDA antagonist improves overall cognition in symptomatic patients.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
Clinical, P2 data, Journal: NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). (Pubmed Central) - Apr 14, 2021
P2
Results will be published in peer-reviewed journals and uploaded to the European Union Clinical Trials Register. ISRCTN10996604, NCT03837977, EudraCT Number: 2017-002453-11.
- |||| etrumadenant (AB928) / Arcus Biosci, Gilead, quemliclustat (AB680) / Arcus Biosci, Gilead
Enrollment open, Metastases: ARC-9: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Apr 13, 2021
P1b/2, N=250, Recruiting, Sponsor: Arcus Biosciences, Inc.
ISRCTN10996604, NCT03837977, EudraCT Number: 2017-002453-11. Not yet recruiting --> Recruiting
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
[VIRTUAL] Real-World Characteristics and Outcomes of Patients with Metastatic Ductal Adenocarcinoma (MPDAC) Treated with Liposomal Irinotecan-Based Regimens By Race () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_380;
Similarly, results from the pivotal phase 3 study, NAPOLI-1, and recent literature suggest that participants of East Asian ethnic origin experience better outcomes than other ethnic groups with liposomal irinotecan+5-fluorouracil/leucovorin following gemcitabine...CONCLUSIONS : This analysis found racial disparities may persist in survival outcomes among patients with mPDAC treated with liposomal irinotecan-based regimens. Further studies are needed to characterize and understand the biological and socio-economic factors contributing to these disparate outcomes.
- 5-fluorouracil / Generic mfg.
[VIRTUAL] 5-Fluorouracil-induced Hand-Foot Syndrome Mimicking Gottron's Papules () - Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_423;
Patients with this form of HFS are at risk of being misdiagnosed with dermatomyositis (DM) given their underlying malignancy. Recognizing that 5-FU and capecitabine can cause HFS affecting the dorsal hand may prevent unnecessary DM work-up in patients receiving these medications.
- | New P2 trial, Metastases: MEND-IT: Induction Chemotherapy for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 9, 2021
P2, N=128, Not yet recruiting, Sponsor: Catharina Ziekenhuis Eindhoven
- | Trial completion: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Apr 8, 2021
P=N/A, N=30, Completed, Sponsor: Philip Philip
Recognizing that 5-FU and capecitabine can cause HFS affecting the dorsal hand may prevent unnecessary DM work-up in patients receiving these medications. Active, not recruiting --> Completed
- | Venclexta (venetoclax) / Roche, AbbVie, emilumenib succinate (DS-1594) / Daiichi Sankyo
Enrollment open, Trial initiation date, Combination therapy: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 7, 2021
P1/2, N=122, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Mar 2021
- | New P3 trial: Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. (clinicaltrials.gov) - Apr 7, 2021
P3, N=600, Not yet recruiting, Sponsor: Fudan University
- || irinotecan / Generic mfg.
Clinical, Journal: Pancreatic ductal adenocarcinoma: tumor regression grading following neoadjuvant FOLFIRINOX and Radiation. (Pubmed Central) - Apr 7, 2021
Several traditional pathology parameters fail to predict OS in patients treated with chemoradiation, while a quantitative tumour-to-tumour bed ratio is a powerful predictor of OS. The data support a two-tiered approach to TRG based on tumour-to-tumour bed ratio, and quantitative analysis merits further consideration.
- | methotrexate / Generic mfg.
Preclinical, Journal: Long-term clinically relevant rodent model of methotrexate-induced cognitive impairment. (Pubmed Central) - Apr 7, 2021
These results demonstrate a significant negative impact of methotrexate on the oligodendrocyte compartment and white matter, associated with cognitive impairment. The data also support the use of diffusion tensor imaging in monitoring white matter integrity in this context.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
Clinical, Clinical data, Journal: Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. (Pubmed Central) - Apr 7, 2021
Liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (5-FU/LV) has shown clinical benefit in patients with metastatic pancreatic adenocarcinoma (mPAC) who progressed on gemcitabine-based chemotherapy...Nal-IRI plus 5-FU/LV showed modest effectiveness and manageable toxicities for patients with mPAC previously treated with conventional irinotecan-containing chemotherapy. The cumulative dose of prior conventional irinotecan therapy may be inversely correlated with the effectiveness of nal-IRI plus 5-FU/LV.
- ||| cisplatin / Generic mfg.
Clinical, P3 data, Journal: Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. (Pubmed Central) - Apr 7, 2021
P3
To our knowledge, this trial is the first prospective, randomised study providing reliable, high-quality evidence to allow an informed discussion with patients of the potential benefits and risks from second-line FOLFOX chemotherapy in advanced biliary tract cancer. Based on these findings, FOLFOX should become standard-of-care chemotherapy in second-line treatment for advanced biliary tract cancer and the reference regimen for further clinical trials.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P3 data, Journal, HEOR, Mismatch repair, Microsatellite instability: Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. (Pubmed Central) - Apr 7, 2021
P3
Pembrolizumab monotherapy led to clinically meaningful improvements in HRQOL compared with chemotherapy in patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. These data, along with the previously reported clinical benefits, support pembrolizumab as a first-line treatment option for this population.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial: FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases (clinicaltrials.gov) - Apr 5, 2021
P2, N=160, Recruiting, Sponsor: Fudan University
- | Enrollment closed, Metastases: GEMPAX: Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Apr 5, 2021
P3, N=211, Active, not recruiting, Sponsor: UNICANCER
These data, along with the previously reported clinical benefits, support pembrolizumab as a first-line treatment option for this population. Recruiting --> Active, not recruiting
- || irinotecan / Generic mfg.
Clinical, Journal, HEOR, Real-world evidence: Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy. (Pubmed Central) - Apr 2, 2021
Total health care costs for patients with mPDA who initiated FFX or AG are driven mostly by outpatient rather than inpatient costs. Further research, using comparative methodology, is warranted to fully understand cost drivers and whether higher costs for FFX patients relate primarily to use of FFX or higher underlying use of outpatient care among FFX patients.
- | irinotecan / Generic mfg.
Preclinical, Journal: Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. (Pubmed Central) - Apr 2, 2021
P1
ECT thus results in synergistic antitumor activity compared with either treatment modality used alone, resulting in increased tumor cell apoptosis as well as decreased tumor cell proliferation and improved overall survival. Pilot data suggest that ECT represents a promising modality for the treatment of patients with locally advanced pancreatic cancer.
- || irinotecan / Generic mfg.
Clinical, Journal: Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. (Pubmed Central) - Apr 1, 2021
Pilot data suggest that ECT represents a promising modality for the treatment of patients with locally advanced pancreatic cancer. Our model seems to be effective for the xenotransplantation of PDAC tissue and evaluation of the effect of each chemotherapy scheme on the xenotransplanted tumor tissue.
- |||| Natrunix (vilamakitug) / XBiotech
New P1/2 trial: 1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 1, 2021
P1/2, N=69, Not yet recruiting, Sponsor: XBiotech, Inc.
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Journal: Tolerability of pemetrexed and oxaliplatin in the treatment of stage III colon cancer during raltitrexed shortage. (Pubmed Central) - Mar 30, 2021
However, the patient also experienced progressive neuropathy which required a dose reduction and subsequent discontinuation of oxaliplatin. Overall, pemetrexed and oxaliplatin's tolerability seems comparable to other regimens used to treat colorectal cancer and could potentially be an option to consider in the future for alternative treatment of colorectal cancer pending further trials.
- || Biomarker, Review, Journal, Tumor microenvironment: Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. (Pubmed Central) - Mar 30, 2021
Furthermore, aberrant HH signaling activation is favorable to both the proliferation of cancer stem cells (CSCs) and the drug resistance of gastrointestinal tumors. This review discusses the current understanding of the role and mechanism of aberrant HH signaling activation in gastrointestinal carcinogenesis, the gastrointestinal TME, tumor immune tolerance and drug resistance and highlights the underlying therapeutic opportunities.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Trial completion date, Trial primary completion date: T2317: Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy (clinicaltrials.gov) - Mar 30, 2021
P2, N=59, Active, not recruiting, Sponsor: National Health Research Institutes, Taiwan
This review discusses the current understanding of the role and mechanism of aberrant HH signaling activation in gastrointestinal carcinogenesis, the gastrointestinal TME, tumor immune tolerance and drug resistance and highlights the underlying therapeutic opportunities. Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021